NOVAS FERRAMENTAS PARA UM DIAGNÓSTICO MAIS PRECISO E TRATAMENTO PERSONALIZADO DO CÂNCER DE MAMA O PAPEL DOS MARCADORES TUMORAIS
DOI:
https://doi.org/10.36557/pbpc.v3i2.271Keywords:
Diagnosis, Breast Neoplasms, Tumor BiomarkersAbstract
Early diagnosis of breast cancer is essential to increase the chances of a cure. However, conventional diagnostic methods, such as mammography and ultrasound, have limitations and may not detect tumors in their early stages. This research consists of an integrative review of the literature. The guiding question was formulated: "What are the new tools for more accurate diagnosis and personalized treatment of breast cancer, and what role do tumor markers play in this regard?". The research was conducted in the databases of the Virtual Health Library (VHL), selecting articles from the following sources: Latin American and Caribbean Literature in Health Sciences (LILACS) and Medical Literature Analysis and Retrieval System Online (MEDLINE). Eleven articles were selected to be included in this review. According to the studies found, advances in the diagnosis and treatment of breast cancer have been accelerated by discoveries in the field of tumor markers, offering new tools that allow a more accurate and personalized approach to the disease. Tumor markers, molecules present in blood, tissues or body fluids, provide essential information about the behavior and characteristics of the tumor, facilitating early diagnosis and the choice of appropriate therapies. As a result, advances in breast cancer diagnostic and treatment tools, especially through the use of tumor markers, have transformed the way the disease is approached in clinical practice.
References
DOURADO, C. A. R. O. Et al. Câncer de mama e análise dos fatores relacionados aos métodos de detecção e estadiamento da doença. Cogitare enfermagem, v. 27, 2022. Disponível em: https://www.scielo.br/j/cenf/a/GZNBprgFShL9RKcTmLq7SSB/#
FREITAS, I. L. Et al. Avanços em marcadores tumorais no diagnóstico e tratamento do câncer de mama. Brazilian journal of implantology and health sciences, v. 6, n. 5, 2024. Disponível em: https://doi.org/10.36557/2674-8169.2024v6n5p2278-2295.
SUKUMAR, J. Et al. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Rev Anticancer Ther, v. 21, n. 2, p. 135-148, 2021. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33198517/.
MARCHIÓ, C. et al. Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol, v. 72, p. 123-135, 2021. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32112814/.
MATHEWS, A. C. et al. CIMINO-MATHEWS, Ashley. Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls. Mod Pathol, v. 34, p. 62- 77, 2021. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33110239/.
FERRARI, P. Et al. Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC. Int J Mol Sc., v. 23, n. 3, 2022. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35163586/.
SANTOS, C. M. C. et al. A estratégia PICO para a construção da pergunta de pesquisa e busca de evidências. Revista Latino-Americana, v. 15, n. 3, 2007. Disponível em: https://revistas.usp.br/rlae/article/view/2463.
OUZANNI, M. et al. Rayyan-a web and mobile app for systematic reviews. Syst. Revis, v. 5, n. 1, 2010. Disponível em: https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-016-0384-4.
FOITZICK, R. V. Et al. Exercise reduces physical alterations in a rat model of fetal alcohol spectrum disorders. Biol. Res., v. 57, n. 1, 2024. Disponível em: https://pesquisa.bvsalud.org/portal/resource/pt/mdl-38907274.
LI, X. Et al. NSG2: a promising prognostic marker shaping the immune landscape of breast cancer. Front immunol, v. 15, 2024. Disponível em: https://pesquisa.bvsalud.org/portal/resource/pt/mdl-39493764.
JAIN, P. V. Et al. Immunohistochemistry in the differential diagnosis of triple negative breast carcinoma and high-grade serous carcinoma: old new markers. Apple immunohistochem mol morphol, v. 32, n. 10, p. 456-461, 2024. Disponível em: https://pesquisa.bvsalud.org/portal/resource/pt/mdl-39506288.
HOU, Q. Et al. Comprehenrive single-cell and bulk transcriptomic analyses to develop and NK cell-derived gene signature for prognostic assessment and precision medicine in breast cancer. Front immunol, v. 15, 2024. Disponível em: https://pesquisa.bvsalud.org/portal/resource/pt/mdl-39507529.
DMELLO, R. Et al. Untargeted metabolomic profiling of small extracellular vesicles revels potential new biomarkers fo triple negative breast cancer. Metabolomics, v. 20, n. 6, p. 123, 2024. Disponível em: https://pesquisa.bvsalud.org/portal/resource/pt/mdl-39487276.
SINGH, M. D. Et al. Refletion mode polarimetry guides laser mass spectrometry to diagnostically important regions of human breast cancer tissue. Sci rep., v. 14, n. 1, 2024. Disponível em: https://pesquisa.bvsalud.org/portal/resource/pt/mdl-39482347.
ULLOA, A. M. Et al. Evaluation of a proteomics-guided pretein signature for breast cancer detection in breast tissue. J proteome res, v. 23, n. 11, 2024. Disponível em: https://pesquisa.bvsalud.org/portal/resource/pt/mdl-39412830.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Maria Eduarda Wanderley de Barros Silva, Isis Nicolle de Holanda Santos Cordeiro, Maria Rita de Lima Silva, Ellen Renata Gomes Silva, Samara Freitas Araújo, José Modesto Júnior de Medeiros, Jéssica Freitas Vieira Neves Ferreira, Eugênio Barros Bortoluzi, Maria Clara Oliveira Padilha Diniz, Marcela Lourenço Lacerda, Gabriella Conceição Alves de Lima
This work is licensed under a Creative Commons Attribution 4.0 International License.
Você tem o direito de:
- Compartilhar — copiar e redistribuir o material em qualquer suporte ou formato para qualquer fim, mesmo que comercial.
- Adaptar — remixar, transformar, e criar a partir do material para qualquer fim, mesmo que comercial.
- O licenciante não pode revogar estes direitos desde que você respeite os termos da licença.
De acordo com os termos seguintes:
- Atribuição — Você deve dar o crédito apropriado , prover um link para a licença e indicar se mudanças foram feitas . Você deve fazê-lo em qualquer circunstância razoável, mas de nenhuma maneira que sugira que o licenciante apoia você ou o seu uso.
- Sem restrições adicionais — Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.
